João Pedro Ferreira, Francisco Vasques-Nóvoa, Christiane E. Angermann, Jan Biegus, Sean P. Collins, Mikhail Kosiborod, Michael E. Nassif, Mitchell A. Psotka, Jasper Tromp, Robert J. Mentz, Piotr Ponikowski, John R. Teerlink, Adriaan A. Voors
{"title":"Low blood pressure and the effect of empagliflozin in acute heart failure: An EMPULSE analysis","authors":"João Pedro Ferreira, Francisco Vasques-Nóvoa, Christiane E. Angermann, Jan Biegus, Sean P. Collins, Mikhail Kosiborod, Michael E. Nassif, Mitchell A. Psotka, Jasper Tromp, Robert J. Mentz, Piotr Ponikowski, John R. Teerlink, Adriaan A. Voors","doi":"10.1002/ejhf.3626","DOIUrl":null,"url":null,"abstract":"Empagliflozin improves outcomes in acute heart failure (AHF). Patients with AHF and low blood pressure (BP) have poor prognosis. Whether empagliflozin is effective and safe in patients with AHF and low BP is currently unknown. The aim of this study was to assess the efficacy and safety of empagliflozin (vs. placebo) in patients with low BP – either systolic BP (SBP) <110 mmHg or diastolic BP (DBP) <70 mmHg – at randomization.","PeriodicalId":164,"journal":{"name":"European Journal of Heart Failure","volume":"89 1","pages":""},"PeriodicalIF":16.9000,"publicationDate":"2025-02-20","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"European Journal of Heart Failure","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.1002/ejhf.3626","RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q1","JCRName":"CARDIAC & CARDIOVASCULAR SYSTEMS","Score":null,"Total":0}
引用次数: 0
Abstract
Empagliflozin improves outcomes in acute heart failure (AHF). Patients with AHF and low blood pressure (BP) have poor prognosis. Whether empagliflozin is effective and safe in patients with AHF and low BP is currently unknown. The aim of this study was to assess the efficacy and safety of empagliflozin (vs. placebo) in patients with low BP – either systolic BP (SBP) <110 mmHg or diastolic BP (DBP) <70 mmHg – at randomization.
期刊介绍:
European Journal of Heart Failure is an international journal dedicated to advancing knowledge in the field of heart failure management. The journal publishes reviews and editorials aimed at improving understanding, prevention, investigation, and treatment of heart failure. It covers various disciplines such as molecular and cellular biology, pathology, physiology, electrophysiology, pharmacology, clinical sciences, social sciences, and population sciences. The journal welcomes submissions of manuscripts on basic, clinical, and population sciences, as well as original contributions on nursing, care of the elderly, primary care, health economics, and other related specialist fields. It is published monthly and has a readership that includes cardiologists, emergency room physicians, intensivists, internists, general physicians, cardiac nurses, diabetologists, epidemiologists, basic scientists focusing on cardiovascular research, and those working in rehabilitation. The journal is abstracted and indexed in various databases such as Academic Search, Embase, MEDLINE/PubMed, and Science Citation Index.